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Conjugated linoleic acids: why the discrepancy between animal
and human studies?
Mélanie Plourde, Stephanie Jew, Stephen C Cunnane, and Peter JH Jones
Conjugated linoleic acids (CLA) are positional and geometric isomers of linoleic acid.
In animals, CLA consumption reduces body fat but results in humans are less
conclusive. This review of the literature on CLA and loss of body fat or bodyweight in
humans was conducted to explore the reasons for the discrepancy between animal
and clinical trials. It indicates that the incongruity between human and animal data
is largely related tomethodological diﬀerences in the experimental design, including
age and gender and, to a lesser extent, to CLA dose and isomers. The relatively
unknown metabolic fate of CLA in humans may also be a contributing factor that
helps explain the lack of consistency for CLA eﬃcacy across studies.
© 2008 International Life Sciences Institute
INTRODUCTION
Conjugated linoleic acids (CLA) are a group of polyun-
saturated fatty acids with a single pair of conjugated
double bonds.1 CLA are found in ruminant meat and
milk products (about 0.4% and 1% of total lipids, respec-
tively). The major natural CLA isomer is 18:2 cis-9,trans-
11, or rumenic acid (RA: Figure 1A). Chemically
synthesized CLA mixtures are also available and are
usually composed of a 50:50 mixture of RA and 18:2
trans-10,cis-12 (Figure 1B). Over the past 20 years,
numerous studies conducted with rodents, pigs, and
chickens have shown that CLA, at doses ranging from 0.5
to 1.0% of total dietary fat, reduces body fat in compari-
son to vegetable oils free of CLA.2–6
Over at least the past 7 years, attempts to replicate
these results in humans have produced inconsistent
results. Recently, a meta-analysis of human trials con-
cluded that at an average dose of 3.2 g/d CLA reduces
body fat mass (FM) by 3–4 g/d for each gram of CLA
consumed.6 However, 12 papers were not included in this
meta-analysis, either because they were published after
the meta-analysis or because they did not meet the inclu-
sion criteria chosen for the meta-analysis.6 Among the 12
papers not reviewed in themeta-analysis, three reported a
loss of 2–8% of FM,7–10 but none of these papers reported
signiﬁcant losses of body weight (BW) with CLA supple-
mentation. Hence, the purpose of the present review was
to re-evaluate the available data concerning loss of FM
and/or BW following CLA supplementation in humans
in order to provide a possible explanation for the incon-
sistent data reported for humans and animals.
CLA AND LOSS OF BODYWEIGHT OR FAT MASS
Normal-weight humans
Studies reporting BW and fat loss (FL) in normal-weight
humans given CLA are shown in Table 1. In all of these
studies, normal weight was deﬁned as a body mass index
of 20–25 kg/m2. To date, we are not aware of studies
reporting BW loss in normal-weight humans given 0.6–
6 g/d CLA for periods of 4–14 weeks, regardless of
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whether the CLA was provided as a mixture of two or
four CLA isomers, or as a single isomer9,11–23 (Table 1). A
loss of body FM in normal-weight subjects was reported
in ﬁve of nine trials after CLA intake.9,13,15,16,22 Three of
these studies resulted in a FM loss of 4%,9,13,15 one showed
a FL of 8%22 and the ﬁfth reported a FM loss of 20%.16
However, two of these studies had potential confounders
because the subjects in both the CLA and the control
groups were undergoing physical training three times/
week.9,16 Colakoglu et al.22 also reported that subjects who
were both taking CLA and doing physical training expe-
rienced a cumulative eﬀect on BW and FM loss.
Overweight and obese humans
BW and FM loss in overweight and obese humans given
CLA are summarized in Table 2. Overweight was deﬁned
in all studies as a body mass index of 25–30 kg/m2, and
obesity was deﬁned as a body mass index >30 kg/m2. In
overweight and obese subjects, 4 of 16 studies10,24–26
reported statistically signiﬁcant BW loss (3% in all
cases) during CLA supplementation, but the remaining
11 studies showed no signiﬁcant eﬀect. Seven of the 16
studies reported a loss of 2–6% of body FM during CLA
supplementation (Table 2), amongst which four demon-
strated loss of both BW and body FM following CLA
intake.10,24–26 Thus, there is minimal evidence supporting
weight loss in normal-weight, overweight, and obese sub-
jects following CLA supplementation (Tables 1 and 2), yet
approximately 50% of the studies claim losses of FM after
CLA intake in normal, overweight, and obese subjects.
Thus, it may be possible that CLA intake leads to a loss of
body fat but, unless new, stronger evidence emerges, CLA
supplementation should not yet be considered either as a
BW and/or FL agent in humans.
INCONSISTENCIES IN EXPERIMENTAL DESIGN
Variations in experimental design may explain observed
diﬀerences in BW and FM loss across animal versus
Figure 1 Chemical structures of A) rumenic acid, 18:2 cis-9,trans-11 and B) 18:2 trans-10,cis-12.
Table 1 Weight and fat mass loss in normal-weight human subjects.
Reference Subjects /
groups
Gender (M/F) Dose (g/d) CLA supplement Duration
(weeks)
WL (% ) FL (%)
Zambell et al. (2000)19 17 0\17 3.0 Four isomers* 9 NS NS
Benito et al. (2001)12 10 0\10 3.9 Four isomers* 13 NS ND
Mougios et al. (2001)13 12 7\5 0.7 CLA mixture† 4 NS NS
Mougios et al. (2001)13 12 7\5 0.7–1.4 CLA mixture† 4 + 4 NS -4%
Thom et al. (2001)16 20 10\10 1.8 CLA mixture† 12 NS -20%
Smedman et al. (2001)15 26 15\11 4.2 CLA mixture† 12 NS -4%
Noone et al. (2002)20 16 6\10 3.0 CLA mixture† 8 NS ND
Belury et al. (2003)11 21 NM 6.0 CLA mixture† 8 NS ND
Petridou et al. (2003)21 16 0\16 2.1 CLA mixture† 6 NS NS
Tricon et al. (2004)18 39–49 NM 0.6–2.4 RA 8 NS NS
Tricon et al. (2004)18 NM 0.6–2.5 18:2 trans-10,cis-12 8 NS NS
Colakoglu et al. (2006)22 44 0/44 3.6 CLA mixture† 6 NS -8%
Tricon et al. (2006)17 32 32\0 1.4 RA 6 NS ND
Pinkoski et al. (2006)9 38 19/19 5.0 CLA mixture† 7 NS -4%
Lambert et al. (2007)23 64 26/38 3.9 CLA mixture† 12 NS NS
Nazare et al. (2007)14 21 NM 3.8 CLA mixture† 14 NS NS
* Mixture of four CLA isomers: RA, 18:2 trans-10,cis-12, 18:2 cis-11,trans-13, 18:2 trans-8,cis-10.
† CLA mixture is composed of rumenic acid (RA) and 18:2 trans-10,cis-12.
Abbreviations: CLA, conjugated linoleic acid; F, female; FL, fat loss; M, male; RA, rumenic acid; ND, not determined; NM, not mentioned;
NS, not signiﬁcant; WL, weight loss.
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human trials. Inconsistencies in age, gender, and genetic
predisposition to fat accumulation in the experimental
design also exist between animal and human trials. For
example, growing mice accumulate 70% less body fat on a
diet containing 0.5 weight % of a 50:50 CLA mixture of
RA and 18:2 trans-10,cis-12, compared to controls given
corn oil.28 However, the ﬁrst human trials attempting to
link CLA supplementation to body FL were all conducted
in adult men.19,29,30 Among these three trials, only one30
achieved signiﬁcance for FM loss. Thus, in animal trials,
mice were in a growing state, i.e., approximately equiva-
lent to the adolescent stage in humans, whereas in the
human trials, weight-stable adults were utilized. Such dif-
ferences in developmental state may confound the results,
because there are important diﬀerences in metabolic rate,
growth rate, and energy requirements between these two
physiological states.
Also, CLA-induced loss of body fat in growing mice
may depend on the proportion of brown adipose tissue
in young mice,31 a depot which is lost in older animals
and does not occur beyond infancy in humans.32 Brown
adipose tissue is used mainly for energy and heat produc-
tion in young animals and human infants.32
Gender may also inﬂuence the eﬃcacy for weight
loss in humans. In animals, Park et al.28 assumed that male
and female mice were equally sensitive to CLA-induced
body fat gain. However, in humans, ﬁve of the clinical
trials in which CLA induced loss of body fat in over-
weight and obese subjects, had 2–5 times more women
than men,8,10,24,25,30 suggesting that gender aﬀects body FL.
On the other hand, one CLA study with a female : male
ratio of 2 reported no body FL.33 Three of these studies
were among the largest published human CLA feeding
trials (Table 2).8,24,25 However, no one has directly evalu-
ated whether gender impacts the eﬃciency of CLA for
FM loss in humans.
Another factor that may inﬂuence body FL is genetic
predisposition to fat accumulation.In rats givenCLAat 0.5
weight % of the diet, those with a genetic predisposition to
fat accumulation such as obese Zucker rats, had retroperi-
toneal fat pads that were 15% heavier than those of obese
Zucker rats on control diets.Yet inwild-type (lean) Zucker
rats given CLA, retroperitoneal fat pads were 24% smaller
compared to controls.34 Hence, it was suggested that a
genetic predisposition to fat accumulation could play an
important role in the eﬀectiveness of CLA in rats. To our
knowledge, no human trials using CLA supplementation
have tried to match genetic predisposition to fat accumu-
lation with eﬃcacy of CLA on body FL or risk factors for
other diseases such as atherosclerosis.
It would be of interest to see if CLA given to humans
regulates genes of lipid metabolism such as fatty acid-
Table 2 Weight and fat mass loss in trials with over weight and obese human subjects.
Reference Subjects /
groups
Gender
(M/F)
Dose (g/d) CLA supplement Duration
(weeks)
WL
(%)
FL
(%)
Berven et al. (2000)29 47 3.4 CLA mixture† 12 NS ND
Blankson et al. (2000)30 12 4\8 1.7 CLA mixture† 12 NS -3%
Blankson et al. (2000)30 8 3\5 3.4 CLA mixture† 12 NS -6%
Blankson et al. (2000)30 11 4\7 5.1 CLA mixture† 12 NS NS
Blankson et al. (2000)30 11 4\7 6.8 CLA mixture† 12 NS -4%
Riserus et al. (2001)60 14 14\0 4.2 CLA mixture† 4 NS ND
Riserus et al. (2002)26 19 19\0 3.4 CLA mixture† 12 NS -3%
Riserus et al. (2002)26 19 19\0 3.4 18:2 trans-10,cis-12 12 -1% -3%
Gaullier et al. (2004)24 61 10\51 3.6 CLA mixture† 52 -1% -5%
Riserus et al. (2004)27 13 13\0 3.0 RA 12 +2% NS
Malpuech-Brugere et al. (2004)39 18 NM 1.5–3.0 RA 6 NS NS
Malpuech-Brugere et al. (2004)39 15 NM 1.5–3.0 18:2 trans-10,cis-12 6 NS NS
Desroches et al. (2005)41 16 16\0 2.6 RA 4 NS ND
Gaullier et al. (2005)25 46 10\36 3.4 CLA mixture† 104 -2% -6%
Naumann et al. (2006)40 34 NM 3.0 RA 13 NS ND
Naumann et al. (2006)40 19 NM 3.0 18:2 trans-10,cis-12 13 NS ND
Taylor et al. (2006)61 21 21\0 4.5 CLA mixture† 12 NS NS
Gaullier et al. (2007)8 55 11\44 3.4 CLA mixture† 24 NS -2%
Laso et al. (2007)7 10 6/4 3.0 CLA mixture† 12 NS -2%
Laso et al. (2007)7 10 9/1 3.0 CLA mixture† 12 NS NS
Steck et al. (2007)62 16 3.2–6.4 CLA mixture† 12 NS NS
Syvertsen et al. (2007)33 27 7\17 4.5 CLA mixture† 24 NS NS
Watras et al. (2007)10 22 5/17 3.2 CLA mixture† 24 -1% -4%
† CLA mixture is composed of rumenic acid (RA) and 18:2 trans-10,cis-12.
Abbreviations: CLA, conjugated linoleic acid; F, female; FL, fat loss; M, male; RA, rumenic acid; ND, not determined; NM, not mentioned;
NS, not signiﬁcant; WL, weight loss.
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binding protein, peroxisomal proliferator-activator
receptor, or fatty acid synthase, which could help our
understanding of the precise roles for CLA in biological
and physiological processes and assist in explaining the
inter-individual responsiveness. Another factor that may
inﬂuence the outcome of the clinical trials is the caloric
intake of the subjects. In animal studies, the caloric intake
is usually well controlled and/or monitored. In some
animal studies, food is provided ad libitum, i.e., intakes
are not controlled but at least the amount of food con-
sumed is monitored and the daily nutritional value is
known because the animal has eaten only one type of
food. In contrast, human trials performed to date have
failed to control and/or monitor the dietary intake of the
subjects for the whole experimental period.
Thus, the lack of reproducibility between animal and
clinical trials using CLA to lower BW and FM may be
largely inﬂuenced by age, gender, and genetic predisposi-
tion to fat accumulation, but results may also be inﬂu-
enced by other confounders such as dietary intake.
Diﬀerences between experimental designs used in animal
and human trials may contribute to low reproducibility of
BW and FL results obtained in animal studies compared
to clinical trials.The poor reproducibility between human
trials is also possibly linked to diﬀerences in experimental
design. For instance, most of the clinical studies that
report a loss of either weight or FM were conducted in
Norway or Sweden,8,15,16,24–26,30 so the environmental back-
ground of the subjects, such as their country and culture,
could have been confounders in an unknown way.
WHICH CLA DOSE AND ISOMER(S) SHOULD BE USED?
In the human trials demonstrating statistically signiﬁcant
weight10,24–26 and body fat7–11,15,16,22,24–26,30 losses after CLA
intake, the average dose was 3.2 g/d,6 which is more than
10 times the habitual normal (0.1–0.3 g/d) intake of CLA
in humans.1 There is no indication to date that the CLA
dose given to humans was too low (generally between
0.5 and 1% of dietary lipids) to be able to reproduce in
humans the loss of weight and fat observed in animals.
Apart from the CLA dose, diﬀerent mixtures of CLA
isomers may contribute to diﬀerent outcomes of clinical
trials, since some single CLA isomers or mixtures have
opposing eﬀects.18,35 Considering that most CLA supple-
ments are chemically synthesized and would thus contain
impurities such as trans, trans CLA, puriﬁcation of the
mixtures is essential because trans, trans CLA might be
toxic to humans if consumed in large quantities.35
Usually, CLA exists as a mixture of two isomers (50:50 of
RA and 18:2 trans-10,cis-12). However, several animal
studies have suggested that the single conjugated isomer
18:2 trans-10,cis-1236–38 is the body fat-lowering agent,
whereas RA is proposed to be implicated more in growth
modulation.38
Some human trials have thus been designed to study
the question of whether one CLA isomer is more potent
to lower body FM than another. Of four human trials
using pure 18:2 trans-10,cis-12,18,26,39,40 only one reported
a loss of weight and FM.26 Six clinical trials used either
pure RA18,27,39,40 or dairy products naturally enriched in
RA17,41 and none reported a loss of weight. Moreover,
none of these studies reported a gain of lean body mass
following the intake of RA, as was observed in an animal
study using pure RA.38
Thus, although a CLA isomer-dependant eﬀect for
body FL has been suggested in animals, in humans, clear
evidence to support this hypothesis is lacking, suggesting
that the incongruity between the results obtained in
animals and humans for body FLmay be in part related to
the CLA isomer used. Thus, diﬀerences in experimental
design may contribute importantly to the incongruity
across data.
METABOLIC FATE OF CLA
The lack of knowledge about the mechanisms by which
single isomers or mixtures of CLA induce body FL in
animals and in a few clinical trials may also contribute to
this discrepancy as well as to the unknown metabolic fate
of CLA after ingestion. In animal studies, the absorption
of CLA given either as a free fatty acid or as a triglyceride
was around 99%, whether assessed by lymphatic recov-
ery42 or fecal analysis after CLA supplementation.43 In
animals, CLA are incorporated similarly to oleic acid into
diﬀerent organs, preferentially accumulating in neutral
lipids.44 The only study reporting CLA absorption in
humans showed that incorporation into chylomicrons of
CLA given as ethyl esters was almost 50% less than CLA
given as a triglyceride.45 In humans, CLA are incorpo-
rated into plasma and leukocyte lipids in proportion to
dietary intake46,47 and have also been identiﬁed in milk
and breast adipose tissue.48,49 Aside from these few
studies, the metabolic fate of CLA in humans remains
largely unknown. Without knowing the exact process of
disposal of CLA, potential heterogeneity in such a system
between and within subjects cannot be evaluated, which
could account for variations in metabolism and, thus, in
eﬃcacy of CLA. Indeed, it is unknown if CLA are either
b-oxidized, elongated or desaturated, or compete with
other fatty acids such as linoleic acid for signalling pro-
cesses in lipid metabolism. In rats, one study has reported
that ~70% of 14C-CLA was completely b-oxidized within
24 h, a rate similar to that of a-linolenic acid, and 18%
more than linoleic acid.50 At present, there are no avail-
able data on the b-oxidation of CLA in humans, partly
due to a lack of availability of suitable tracers for CLA.
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CLA that are not b-oxidized could be elongated and
desaturated in rats. Two animals studies have shown that
conjugated arachidonic acid (ARA) accounted for 5%
and 22% in rats given CLA.51,52 Higher conjugated ARA
was obtained in livers of rats that had been reared on a
fat-free diet for 2 weeks before being fed with 180 mg/day
CLA for 6 days.53 One study reported data on CLA
metabolites in six healthy adult women following con-
sumption of deuterated conjugated CLA mixtures of
ethyl esters. No metabolites of deuterated RA were iden-
tiﬁed but ~5% of 18:2-d4 trans-10,cis-12 was D6 desatu-
rated to 18:3-d4 cis-6,trans-10,cis-12.54 Thus, it appears
that conversion of RA and 18:2 trans-10,cis-12 to conju-
gated ARA in humans is relatively ineﬃcient or does not
occur. Recent data show that the conversion rate of LA to
ARA in humans is less than 0.1%.55 The signiﬁcance of
possibly producing conjugated ARA to explain discrep-
ancies in the results on BW and FL in animals and
humans is partly linked to the role of ARA as a ligand
for nuclear receptors, such as peroxisomal proliferator-
activator receptors and liver X receptor, both of which are
involved in multiple cellular processes such as lipid
anabolism and catabolism.56 CLA is a ligand to peroxiso-
mal proliferator-activated receptors alpha and gamma in
vitro and in vivo.57,58 Considering that the conversion of
CLA to conjugated ARA seems to be very limited both in
animals and humans, this pathway would not seem to
explain the discrepancy between animals and humans for
losses in weight and fat.
CLA increases b-oxidation of other fatty acids in
liver mitochondria and peroxisomes in mice by increas-
ing the expression of speciﬁc enzymes such as carnitine
palmitoyltransferase-1 and acyl coenzyme A.59 However,
none of these mechanisms proposed by animal models
have yet been evaluated in humans. The unknown fate
and poor understanding of the metabolic pathways of
CLA in humans is thus probably part of the explanation
for the ongoing discrepancy in CLA eﬃcacy between
animal and human data.
CONCLUSION
Our assessment of the CLA literature is that body FL is
not consistently observed in human subjects given a CLA
supplement, and that BW loss is rarely observed after
such supplementation. Major reasons for inconsistencies
in the results obtained across animal and human trials
include the substantially diﬀerent experimental designs
utilized in humans compared to animals, the unknown
metabolic fate of CLA, and the absence of conﬁrmed or
even plausible mechanisms by which CLA reduce BW
and FM. For these reasons, we suggest it is inappropriate
to extrapolate to humans results obtained in animals.
Until new evidence emerges addressing current limita-
tions,CLA supplementation should not be recommended
either as a BW and/or a FL agent in humans.
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